<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02939131</url>
  </required_header>
  <id_info>
    <org_study_id>IMPAACT 2002</org_study_id>
    <nct_id>NCT02939131</nct_id>
  </id_info>
  <brief_title>IMPAACT 2002: Combined Cognitive Behavioral Therapy and a Medication Management Algorithm for Treatment of Depression Among US Youth With HIV</brief_title>
  <official_title>IMPAACT 2002: Combined Cognitive Behavioral Therapy and a Medication Management Algorithm for Treatment of Depression Among Youth Living With HIV in the United States</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Maternal Pediatric Adolescent AIDS Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>International Maternal Pediatric Adolescent AIDS Clinical Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      IMPAACT 2002 is a prospective, multi-site, two-arm, cluster-randomized study to evaluate
      whether a health and wellness Cognitive Behavioral Therapy and Medication Management (COMB-R)
      intervention for depression demonstrates improved depression and medical outcomes for
      HIV-infected youth in the US compared to enhanced standard care (ESC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      IMPAACT 2002 is a prospective, multi-site, two-arm, cluster-randomized study to evaluate
      whether a health and wellness Cognitive Behavioral Therapy and Medication Management (COMB-R)
      intervention for depression demonstrates improved depression outcomes (e.g., decreased
      depressive symptoms and greater remission and response rates) and medical outcomes (e.g.,
      increased CD4 T-cell count, decreased HIV RNA level) among HIV-infected youth in the US
      compared to enhanced standard care (ESC). Youth enrolled in the study will attend a
      Screening/Entry Visit and study visits at Weeks 1, 6, 12, and 24. They will have two
      additional follow-up visits at Weeks 36 and 48 for the study team to evaluate if observed
      effects of the intervention are maintained. The intervention is a treatment for depression
      that includes manualized Health and Wellness Cognitive Behavioral Therapy and
      algorithm-driven Medication Management designed to address the unique challenges faced by
      this population.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">March 6, 2017</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Depression Outcomes: Quick Inventory of Depression Symptomatology - Self Report (QIDS-SR) Score</measure>
    <time_frame>Week 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Depression Outcomes: Response to Treatment, defined as a decrease in QIDS-SR score by &gt;50%</measure>
    <time_frame>Week 24</time_frame>
    <description>2) Plasma HIV RNA level</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Depression Outcomes: Remission, defined as a QIDS-SR Score &lt;= 5</measure>
    <time_frame>Week 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Biological Outcomes: CD4 cell count</measure>
    <time_frame>Week 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Biological Outcomes: Plasma HIV RNA Level</measure>
    <time_frame>Week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adherence Outcomes: Adherence to anti-HIV Medications</measure>
    <time_frame>Over 24 and 48 Weeks</time_frame>
    <description>Adherence to anti-HIV medications at each assessment for the first 24 weeks (during active treatment) and at 48 weeks, as measured by self-report</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence Outcomes: Adherence to Psychiatric Medications</measure>
    <time_frame>Over 24 and 48 Weeks</time_frame>
    <description>Adherence to psychiatric medications at each assessment for the first 24 weeks (during active treatment) and at 48 weeks, as measured by self-report</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence Outcomes: Adherence to Study Visits and Psychotherapy Sessions</measure>
    <time_frame>Over 24 and 48 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression Outcomes: QIDS-SR Score over 48 Weeks</measure>
    <time_frame>Over 48 Weeks</time_frame>
    <description>QIDS-SR score (defined above) over 48 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression Outcomes: Response to Treatment over 48 Weeks</measure>
    <time_frame>Over 48 Weeks</time_frame>
    <description>Response to treatment (defined above) over 48 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression Outcomes: Remission over 48 Weeks</measure>
    <time_frame>Over 48 Weeks</time_frame>
    <description>Remission (defined above) over 48 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Demographic, Behavioral, and Biological Modifiers on Depression Outcomes: QIDS-SR Score (defined above)</measure>
    <time_frame>Over 48 Weeks</time_frame>
    <description>Effect of moderators (Demographic: age, gender. Behavioral: HIV acquisition category, initial level of depression; Biological: baseline CD4, nadir CD4, plasma HIV RNA, CDC category) on depression outcomes: QIDS-SR Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Demographic, Behavioral, and Biological Modifiers on Depression Outcomes: Response to Treatment (defined above)</measure>
    <time_frame>Over 48 Weeks</time_frame>
    <description>Effect of moderators (Demographic: age, gender. Behavioral: HIV acquisition category, initial level of depression; Biological: baseline CD4, nadir CD4, plasma HIV RNA, CDC category) on depression outcomes: Response to Treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Demographic, Behavioral, and Biological Modifiers on Depression Outcomes: Remission (defined above)</measure>
    <time_frame>Over 48 Weeks</time_frame>
    <description>Effect of moderators (Demographic: age, gender. Behavioral: HIV acquisition category, initial level of depression; Biological: baseline CD4, nadir CD4, plasma HIV RNA, CDC category) on depression outcomes: Remission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Behavioral Risk Outcomes: Alcohol/Drug Use</measure>
    <time_frame>Weeks 24 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Behavioral Risk Outcomes: Sex-Risk Behaviors</measure>
    <time_frame>Weeks 24 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implementation Fidelity (COMB-R sites); Counseling Strategies (ESC sites)</measure>
    <time_frame>24 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patterns of Psychiatric Medication Use</measure>
    <time_frame>24 and 48 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Interim Counseling Visits</measure>
    <time_frame>24 and 48 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Psychiatric Medication Use</measure>
    <time_frame>24 and 48 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>COMB-R and ESC Acceptability among Participants and Clinicians</measure>
    <time_frame>24 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade 3 or Higher Adverse Events, Psychological Hospitalizations, and Suicide Attempts</measure>
    <time_frame>Over 48 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">156</enrollment>
  <condition>HIV</condition>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>COMB-R</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Health and Wellness Cognitive Behavioral Therapy and Medication Management (COMB-R) intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ESC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Enhanced Standard of Care (ESC)</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Health and Wellness Combined Cognitive Behavioral Therapy and a Medication Management Algorithm</intervention_name>
    <description>Behavioral therapy based on a manualized approach developed specifically for youth living with both HIV and depression, using problem-solving, motivational interviewing and cognitive-behavioral strategies to decrease adherence obstacles and increase wellness. The medication management algorithm includes guidance for clinicians on strategies and tactics to treat depression in this population, including factors to consider when deciding on treatments (i.e., drug-drug interactions, side effects).</description>
    <arm_group_label>COMB-R</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Enhanced Standard of Care</intervention_name>
    <description>Ongoing psychopharmacological and psychosocial counseling and treatment for depression at HIV clinical treatment centers enhanced by providing clinicians with up-to-date information and didactic training on current principles for use of medication and psychotherapy in the treatment of depression.</description>
    <arm_group_label>ESC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Receiving mental health or HIV-related care at participating US IMPAACT site

          -  Confirmed of HIV-1 Infection

          -  Aware of his or her HIV infection

          -  Per clinician assessment, primary diagnosis of nonpsychotic depression, including
             Major Depressive Disorder, Depression NOS, or Dysthymia, as defined by DSM-IV or DSM-V
             criteria

          -  Current depressive symptoms that warrant intervention as determined by a score of â‰¥ 11
             on the Quick Inventory of Depressive Symptomatology - Clinician (QIDS-C)

          -  Able to communicate in spoken and written English

          -  Able and willing to provide written informed assent/consent and able to obtain written
             parental or guardian permission (if required, as specified in site SOP, by State law,
             and/or IRB policy) to be screened for and to enroll in IMPAACT 2002

        Exclusion Criteria:

          -  Known or self-reported history of any psychotic disorder and/or bipolar I or II
             disorder

          -  Severe disorders (more than 6 symptoms) based on DSM-V criteria) related to alcohol,
             cannabis or other substances; or those with moderate symptoms (4 or 5 symptoms) who
             are also currently experiencing withdrawal or dependence symptoms; within the past
             month prior to enrollment

          -  Per clinician assessment at screening, depression and/or suicidal ideation requiring
             more intensive treatment than the study provides or at immediate risk of being a
             danger to themselves or others

          -  Per participant report at screening, intends to relocate away from the study site
             during study participation

          -  Currently in therapy with a non-study provider, unless willing to switch to a
             study-trained provider

          -  Has any other condition that, in the opinion of the Investigator of Record
             (IoR)/designee, would preclude informed assent/consent, make study participation
             unsafe, complicate interpretation of study outcome data, or otherwise interfere with
             achieving the study objectives
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>24 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Larry Brown, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Brown University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Southern California - MCA Center (CRS 5048),</name>
      <address>
        <city>Alhambra</city>
        <state>California</state>
        <zip>91803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University California, San Diego (CRS 4601)</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>David Geffen School of Medicine at UCLA (CRS 5112)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Colorado (CRS 5052)</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Diagnostic and Treatment Center (CRS 5055)</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine (CRS 5030)</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center (CRS 5083)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University School of Medicine (CRS 5092)</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bronx-Lebanon Hospital Center (CRS 5114)</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10457</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jacobi Medical Center (CRS 5013)</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stony Brook University Medical Center (CRS 5040)</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Jude Children's Research Hospital (CRS 6501)</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's/Baylor (CRS 3801)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 7, 2016</study_first_submitted>
  <study_first_submitted_qc>October 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2016</study_first_posted>
  <last_update_submitted>November 15, 2017</last_update_submitted>
  <last_update_submitted_qc>November 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cognitive Behavioral Therapy</keyword>
  <keyword>Medication Management</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

